It is possible that a medication that targets IL-5 might successfully reduce asthma episodes linked to eosinophilia without unduly affecting other aspects of host health because IL-5 seems to be a less pleiotropic cytokine than others [35]. This evidence concerns the gene IL5 and Increased total eosinophil count.